Additionally, the recent proteomic profiling of various cancer patients for circulating proteins has identified other potential circulating tumor protein biomarkers such as thymidine kinases, DNAse activity, circulating nucleosomes, soluble receptors of advanced glycation end products (sRAGE), high-mobility group box 1 (HMGB1), and immunogenic cell death markers [252,253]. This evidence concerns the gene HMGB1 and cancer.